Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results from early-stage trials for its once-weekly obesity treatment, amycretin.

Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin.

Novo Nordisk was harshly criticized by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure to properly disclose payments to health and ...

Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...